

Aristotelis Bamias, M.D., Ph.D.

Professor, School of Medicine, National and Kapodistrian University of Athens



Professor Bamias studied Medicine in the Medical School of the University of Athens and trained in Internal Medicine and Medical Oncology in the United Kingdom, at the Hammersmith, Royal Marsden and St Bartholomew's Hospitals in London. Professor Bamias successfully completed his thesis at the University of Athens and subsequently obtained a PhD from the University of London, working on the application of monoclonal antibodies to cancer diagnosis and treatment. He served as Lecturer in Medical Oncology at the University of London. He is now a practicing medical oncologist in Greece at the 2nd Propaedeutic Department of Internal Medicine of the University of Athens at the ATTIKON University Hospital in Athens. He has been the Director of this Dept from 2019 to 2022.

Professor Bamias's main research focus in oncology is urogenital and gynaecological tumours. He was the coordinator of the genito-urinary working group of the Hellenic Cooperative Oncology Group (HECOG) for 10 years and the representative of HECOG at the European Network Gynaecological Oncological Trial Groups (ENGOT) for 3 years. Professor Bamias is a founding member and currently vice-Chair of the Hellenic Genito-Urinary Cancer Group (HGUCG). He is also a member of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and the Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.

Professor Bamias is a member of the Royal College of Physicians (MRCP, UK), full member of the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO) and the European Society of Gynaecological Oncology (ESGO). He has been a member of the ESMO Faculty for Genitourinary Cancer since 2012 and he chaired this group from 2016 to 2020. He has been member of the scientific committees of ESMO and EMUC Congresses since 2016, invited faculty in the respective congresses and organized several ESMO educational activities. A member of several international advisory boards, steering committees of international trials and Consensus Groups, he has led numerous national and international, industry-sponsored and academic studies and he has published more than 350 original papers and reviews in peer-reviewed journals, including the N Engl J Med, Lancet, Lancet Oncology, J Clin Oncol and Eur Urol with more than 20000 citations by other authors and a current h-index of 71.



Efstathios Kastritis, MD is Professor of Clinical Therapeutics/Medical Oncology at the National and Kapodistrian University of Athens (NKUOA), School of Medicine. He graduated National and Kapodistrian University of Athens School of Medicine and completed residency in Internal Medicine and fellowship in Medical Oncology at the Department of Clinical Therapeutics. He received his Doctorate from the National and Kapodistrian University of Athens and was a post-doctoral Fellow at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. His research focus includes clinical and translational research in plasma cell dyscrasias, especially multiple myeloma, amyloidosis, Waldenström's macroglobulinemia and monoclonal gammopathies of renal and clinical significance, resulting in more than 460 published papers in peer reviewed journals.



Virginia Kaklamani, MD

Professor, Hematology-Medical Oncology, The University of Texas Health Science Center San Antonio and Breast Cancer Program Leader, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center



Virginia Kaklamani, MD, completed her medical training with honors at the University of Athens and her residency in internal medicine at Newton-Wellesley Hospital in Boston. She completed her fellowship in hematology-oncology at Northwestern University. She also received a Master of Science in Clinical Investigation from Northwestern University. She was head of the Translational Breast Cancer Program at Northwestern University and co-director of the cancer genetics program at the same institution.

She has also served as the associate director for clinical research at UT Health San Antonio. Her research interests include designing clinical trials with targeted agents. She has also identified several genetic mutations that link obesity and breast cancer. She is co-director the San Antonio Breast Cancer Symposium, the world's largest breast cancer research symposium.

She was named one of San Antonio's Top Doctors for Women and San Antonio's Top Doctors 2021.

Our Primary Value

The Needs
of the Patient
Come First



Michalis Karamouzis, M.D.

Medical Oncologist, Professor, National and Kapodistrian University of Athens



Besides his clinical work he has organized a Molecular Oncology Unit. He has established a strong research program and created a highly skilled and competent research group. He has also formed collaborations with well-established cancer research scientists. Prof. Karamouzis' lab advanced in the proximity ligation assay technique that can evaluate dimerization of two proteins as well as enhance the signal of low abundant proteins in situ. Additionally, his team is working on improving immunotherapy result and identifying predictive biomarkers in aerodigestive carcinomas.

Prof. Michalis Karamouzis' national and international recognition counts 31 communications in International conferences and 36 in National conferences. He has participated in 18 round tables and was invited and gave 15 lectures in National conferences. He has more than 120 publications in international peer-reviewed journals listed in SCI which a mean impact factor of 8.1. His publications have achieved until now more than 16.000 citations. The H-index is 41.

Prof Karamouzis has also served as a reviewer for many peer-reviewed international journals (such as Ann Oncol, J Clin Oncol, Breast Cancer Res, EurJ Cancer, Lancet Oncol, Cancer Metastasis Rev, and many others). He has also served as an evaluator of scientific project proposals, both national and international.

In the context of the educational proceedings, Prof. Michael Karamouzis teaches in two undergraduate courses in Athens Medical School and Dental School on Biological Chemistry. His main teaching course is carcinogenesis and the impact of various signal transduction pathways in the initiation and progression of malignant tumors.

He is an active ESMO Member, past chair of ESMO Young Oncologists Committee and has participated in various ESMO groups, among them Publication Working Group in which he was one of the Editors of the latest ESMO Essentials





Taxiarchis Kourelis, M.D.

*Associate Professor of Medicine and Oncology,
College of Medicine*



Dr. Kourelis, is currently a clinician in the dysproteinemia disease-oriented group at Mayo Clinic. During his subspecialty training at Mayo he has made several significant clinical and translational research observations in the field. His current research interest focus on translational research in AL and ATTR amyloidosis. More specifically, he uses novel systems-biology approaches to discovering mechanisms of tissue damage in this group of diseases.

Positions and Employment

2006-2007	Research Fellow, University of Thessaly Medical School, Greece
2007-2009	Research Fellow, Department of Pharmacology and Experimental Therapeutics, Tufts Medical School, Boston, MA
2009-2012	Residency-Internal Medicine, University of Connecticut, CT
2012-2015	Hematology/Oncology Fellowship-, Mayo Clinic, Rochester, MN
2015-2016	Myeloma Fellowship, Mayo Clinic, Rochester, MN
2017-06/2019	Senior Associate Consultant, Assistant Professor of Medicine and Oncology, Division of Hematology, Myeloma Group, Mayo Clinic, Rochester, MN
01/2019-	Consultant, Division of Clinical Biochemistry, Special Protein Laboratory, Mayo Clinic, Rochester, MN
2019-2022	Consultant, Assistant Professor of Medicine and Oncology, Division of Hematology, Myeloma Group, Mayo Clinic, Rochester, MN
2022-	Consultant, Associate Professor of Medicine and Oncology, Division of Hematology, Myeloma Group, Mayo Clinic, Rochester, MN

Honors

2014	Conquer Cancer Foundation/ASCO Merit Award
2014	Travel Award. 14 th International Amyloidosis Symposium, Indianapolis, IN.
2014	Small Grants Program Award, Mayo Clinic Department of Medical Oncology
2015	Best Abstract Award Society of Hematology and Oncology (SOHO)
2016	Outstanding Graduating Fellow Award
2016	ASH Clinical Research Training Institute (CRTI) scholar

Evangelos Terpos, M.D., Ph.D.

Professor of Hematology, Director of Stem Cell Transplantation Unit, Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens



Dr. Terpos main research interest is the biology and management of bone disease in multiple myeloma. He also studies the role of modern imaging (MRI, PET/CT) and of MRD in plasma cell neoplasms. In the clinical research era, Dr Terpos participates in many important clinical trials and is the PI of several investigator-initiated studies with novel agents (including belantamab mafodotin, isatuximab and selinexor) in the field of myeloma.

His research work was reported in more than 750 papers in peer-reviewed journals and Dr Terpos has more 37,000 citations and an h-index of 90 in ISI/Web of Knowledge and more than 55,000 citations and an h-index of 109 in Google Scholar.

Dr. Terpos is co-chairing the Bone Sub-Committee of the International Myeloma Working Group and is a member of the Guideline Subgroup of the European Myeloma Network (EMN). Dr Terpos is also a member of the Education and Publication Committees of the International Myeloma Society (IMS), and he is the vice-president of the Greek Myeloma Study Group.

He has given lectures at ASH, ASCO, EHA, IMS and EMN meetings. He is Associate Editor for Myeloma of American Journal of Hematology and of Clinical Lymphoma, Myeloma and Leukemia (official journal of IMS).



Ioannis Varkarakis, MD, PhD, FEBU, ECFMG

Professor of Urology, School of Medicine, National and
Kapodistrian University of Athens



Dr. Ioannis (John) Varkarakis finished Medical School in Athens University, and completed his residency at Sismanoglio Hospital. He continued his training for three years; at the Brady Urological Institute (Baltimore USA) and at the University of Innsbruck (Austria). He is currently working at the 2nd Department of Urology of the National and Kapodistrian University of Athens at Sismanoglio Hospital. His main practice and research interests are on prostate, renal and bladder cancer. He is the author of 120 publications with more than 3000 citations.



Flora Zagouri, M.D., Ph.D.

Professor, Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens



Dr. Zagouri obtained her medical degree from the National and Kapodistrian University of Athens in 2003, completed a residency in medical oncology at the Alexandra Hospital and a fellowship in oncology at the University of Vienna, Austria (AKH Hospital – Comprehensive Cancer Center). Dr Zagouri is a member of numerous scientific societies and has authored more than 300 publications in peer-reviewed journals, as well as numerous abstracts and several textbook chapters primarily focusing on cancer diagnosis during pregnancy and breast cancer. She has more than 4,000 citations. She is a journal reviewer for several journals and evaluator of research proposals submitted to European Research Council. Dr. Zagouri, is Associate editor in several journals. She has participated in more than 45 clinical trials as a Principal Investigator focused on breast and gynecological cancers.



Michalis Lontos, M.D., Ph.D.

Assistant Professor of Oncology, Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens



Dr. Lontos is a Medical Oncologist with a special interest in Gynecologic and Genitourinary Neoplasms. He works as an Assistant Professor at the Department of Clinical Therapeutics, NKUA, Alexandra Hospital, where he carries out his educational, clinical and research work.

He graduated with honors from the Medical School of Athens in 2002. He received his PhD with honors, titled "The Role of Oncogenes in the Induction of Cellular Senescence and Apoptosis in Cancer," part of which was published in the journal Nature. He specialized in Medical Oncology at the Department of Clinical Therapeutics, Alexandra Hospital and obtained his specialty title in 2014. He continued working as a Locum Registrar and Registrar in the same department, participating in the clinical, educational, and research activities of the clinic.

So far, Dr. Lontos has participated in 112 publications - original works, review articles, and clinical cases - in international scientific journals, many of which were published in high-quality journals such as Nature, Nature Cell Biology, Cancer Research, Journal of Clinical Oncology, Lancet Oncology, Annals of Oncology, among others. These publications have received 5421 citations, and his h-index is 29. In addition to his publications, he has given numerous lectures and presentations at national and international conferences. He holds the position of Editor in Chief at the Forum of Clinical Oncology journal, the official journal of the Hellenic Society of Medical Oncologists (HESMO), and he is a member of the Executive Committee of the Hellenic Genito-Urinary Cancer Group (HCUCG).





Sotirios Papageorgiou, M.D., Ph.D.

Assistant Professor, Hematology, School of Medicine,
National and Kapodistrian University of Athens

Dr. Sotirios G. Papageorgiou is an Assistant Professor of Hematology at the School of Medicine of the National and Kapodistrian University of Athens and serves as a Consultant Hematologist at the Hematology Division and Bone Marrow Transplant Unit of the 2nd Department of Internal Medicine at Attikon University Hospital in Athens, Greece. He graduated from the Medical School of Athens University in 1998. From February 2002 to February 2008, he completed his training in Hematology at the 2nd Department of Internal Medicine at Attikon University Hospital. In March 2004 he obtained his MD degree with his thesis on the detection of p16 and p27 gene abnormalities in myelodysplastic syndromes. His research interests include molecular mechanisms as well prognostic biomarkers of myeloid and lymphoid malignancies. He is a member of the Hellenic Society of Hematology and the European Hematology Association. Since January 2024, he has elected president of the section of the lymphoproliferative disorders of the Hellenic Society of Hematology. He has more than 220 presentations at national and international congresses, and he has published more than 130 original and review articles in peer-reviewed scientific journals.

Dr. Karamouzis is Medical Oncologist, Professor in National and Kapodistrian University of Athens.

Besides his clinical work he has organized a Molecular Oncology Unit. He has established a strong research program and created a highly skilled and competent research group. He has also formed collaborations with well-established cancer research scientists. Prof. Karamouzis' lab advanced in the proximity ligation assay technique that can evaluate dimerization of two proteins as well as enhance the signal of low abundant proteins *in situ*. Additionally, his team is working on improving immunotherapy result and identifying predictive biomarkers in aerodigestive carcinomas.

Prof. Michalis Karamouzis' national and international recognition counts 31 communications in International conferences and 36 in National conferences. He has participated in 18 round tables and was invited and gave 15 lectures in National conferences. He has more than 120 publications in international peer-reviewed journals listed in SCI which a mean impact factor of 8.1. His publications have achieved until now more than 16.000 citations. The H-index is 41.

Prof Karamouzis has also served as a reviewer for many peer-reviewed international journals (such as Ann Oncol, J Clin Oncol, Breast Cancer Res, EurJ Cancer, Lancet Oncol, Cancer Metastasis Rev, and many others). He has also served as an evaluator of scientific project proposals, both national and international.

In the context of the educational proceedings, Prof. Michael Karamouzis teaches in two undergraduate courses in Athens Medical School and Dental School on Biological Chemistry. His main teaching course is carcinogenesis and the impact of various signal transduction pathways in the initiation and progression of malignant tumors.

He is an active ESMO Member, past chair of ESMO Young Oncologists Committee and has participated in various ESMO groups, among then Publication Working Group in which he was one of the Editors of the latest ESMO Essentials for Clinicians on Gastrointestinal Cancers.

Meletios A. (Thanos) Dimopoulos, MD is a Hematologist-Medical Oncologist, Chairman of the Department of Clinical Therapeutics and Rector of the National and Kapodistrian University of Athens (from Feb 2015 to Aug 2023). After his graduation from the Medical School of the National and Kapodistrian University of Athens, he continued his training in Internal Medicine at McGill University, Montreal Canada. Subsequently, he did a fellowship in Hematology – Medical Oncology at the MD Anderson Cancer Center, Houston Texas, USA. After his fellowship, he was appointed as Assistant Professor in this Institution. He has a research interest in Plasma Cell Dyscrasias, Malignant Hematology, Genitourinary and Gynecologic Medical Oncology. He has authored more than 1350 publications, he has more than 98000 citations and his h-index is 137. Dr. Dimopoulos serves on the Scientific Advisory Boards of several scientific societies and is a reviewer in multiple Medical Journals. He is a recipient of the Robert A. Kyle Award for outstanding contributions to Waldenstrom's macroglobulinemia, of Waldenstrom's award for Myeloma Research of the International Myeloma Society, of the CoMy Excellence Award and of the Robert Kyle Life Achievement Award. In August 2017 he was given the title "Officier dans l' Ordre des Palmes academiques" (Republique Francaise, Ministere de l' Education Nationale). In May 2018 he was elected as membre associe etranger of the National Academy of Medecine of France. In January 2020 he received the MD Anderson Distinguished Alumnus Award. In February 2020 he was awarded by the President of the Hellenic Republic with the medal of the Grand Commander of the Order of the Phoenix. In October 2022 he was awarded with the title of Doctor Honoris Causa by the University of Belgrade.